Ozarelix

From WikiMD.org
Jump to navigation Jump to search

Ozarelix

Ozarelix (pronounced: oh-zar-eh-lix) is a synthetic decapeptide that acts as an antagonist of the gonadotropin-releasing hormone receptor (GnRHR). It is primarily used in the treatment of prostate cancer and benign prostatic hyperplasia (BPH).

Etymology

The term "Ozarelix" is derived from the combination of the chemical structure of the drug and its therapeutic use. The prefix "Oza-" is derived from the chemical structure of the drug, which is a decapeptide, and "-relix" is a common suffix used for GnRH antagonists.

Pharmacology

Ozarelix works by blocking the action of gonadotropin-releasing hormone (GnRH) on its receptor. This prevents the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland, which in turn reduces the production of testosterone in the testes. This reduction in testosterone levels can help to shrink prostate tumors and relieve symptoms of BPH.

Clinical Use

Ozarelix is used in the treatment of prostate cancer and BPH. It is administered by subcutaneous injection and is typically given once a month. The drug has been shown to be effective in reducing the size of the prostate and improving urinary symptoms in men with BPH. In clinical trials, Ozarelix has also demonstrated efficacy in reducing prostate-specific antigen (PSA) levels in men with prostate cancer.

Related Terms

External links

Esculaap.svg

This WikiMD article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski